Summary
Goodhealth, a New Zealand dietary supplement brand founded in 1987 by botanist John Blanchard, is positioning itself as the country's national nutrition brand with a focus on natural health products. The company's products are stocked in 1,142 pharmacy stores across New Zealand and more than 10,000 pharmacies worldwide, reaching 59 countries and regions. It holds FernMark, Medsafe GMP and RMP certifications, with retail coverage spanning Unichem, Life Pharmacy, Chemist Warehouse and Countdown Pharmacy.
As of 2026, Goodhealth has exhibited at the China International Import Expo for seven consecutive years and is developing cross-border e-commerce and livestreaming. Its flagship Bone Collagen uses UC-II undenatured type II collagen. Research published in Communications Biology in 2024 found that oral undenatured type II collagen works through an 'oral immune tolerance' mechanism, reducing disease incidence to 50 percent in an experimental collagen-induced arthritis model and decreasing expression of pro-inflammatory factors such as IL-17 and IL-22 in joints.
It also protects against intestinal pathology, remodels the IL-17/IL-22 network and regulates intestinal fucosylation and microbiome composition, further confirming the importance of the 'gut-joint axis' in arthritis.
Commentary
Goodhealth, a locally rooted New Zealand nutrition brand, is entering the joint care market with UC-II undenatured type II collagen, reflecting a global shift in the dietary supplement market from basic vitamins to functional, science-backed products. New Zealand's health supplement industry is highly export-dependent, and China is a key growth market. According to New Zealand Trade and Enterprise, China is New Zealand's second-largest export destination for health supplements, with export value of about NZ$320 million in 2024.
Goodhealth is stocked in 1,142 New Zealand pharmacies and has participated in the China International Import Expo for seven consecutive years, demonstrating its long-term commitment to the Chinese market. For NZ small and medium-sized enterprises, this case suggests that in China's highly competitive market, differentiated ingredients and scientific evidence are key to breaking through homogenisation. Compared with traditional hydrolysed collagen, undenatured type II collagen works through an oral immune tolerance mechanism and can reduce arthritis incidence — a selling point that aligns with the needs of China's ageing population and active sports participants.
However, it should be noted that China's market regulation is tightening, health food registration and filing cycles are long, and cross-border e-commerce channels, while convenient, face policy volatility risks. At the same time, Australasian brands in the Chinese market face intense competition from domestic brands such as By-Health and Swisse (which has been acquired by Chinese capital). Goodhealth reaches consumers through new formats such as cross-border livestreaming, offering SMEs a light-asset model worth emulating.
Yet reliance on a single core ingredient may expose it to raw material supply and patent risks. Its subsequent product line expansion and localisation strategy warrant attention.
Keywords: Goodhealth, undenatured type II collagen, joint health, New Zealand pharmacies, China International Import Expo, cross-border e-commerce, UC-II, oral immune tolerance, dietary supplements
Source: The Beijing News Online
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






